Statin administration and risk of cholecystectomy: A population-based case-control study

Expert Opinion on Drug Safety

Volumn 9, Issue 4, 2010, Pages 539-543

  Merzon, Eugene ^a,b   Weiss, Noel S ^c   Lustman, Alex James ^d   Elhayani, Asher ^b,d,e   Dresner, Julian ^b,d   Vinker, Shlomo ^b,d  

^a Department of Family Medicine Leumit HMO ^*  (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF WASHINGTON   (United States)

^d CLALIT HEALTH SERVICES   (Israel)

^e MEIR MEDICAL CENTER   (Israel)

Author keywords

case control; cholecystectomy; gallstone; statins; surgery

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGED; ARTICLE; CHOLECYSTECTOMY; CONTROLLED STUDY; DRUG USE; FEMALE; GALLSTONE; HUMAN; MALE; PATIENT COMPLIANCE; POPULATION RESEARCH; RISK ASSESSMENT; RISK REDUCTION; SOCIAL STATUS; CASE CONTROL STUDY; GALLBLADDER DISEASES; MEDICATION COMPLIANCE; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; CASE-CONTROL STUDIES; CHOLECYSTECTOMY; FEMALE; GALLBLADDER DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDICATION ADHERENCE; MIDDLE AGED;

EID: 77953800586     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2010.485190     Document Type: Article

References (36)

1. Everhart JE, Khare M, Hill M, Maurer KR. Prevalence and ethnic differences in gallbladder disease in the United States. Gastroenterology 1999;117(3):632-639
2. Jorgensen T, Kay L, Schultz-Larsen K. The epidemiology of gallstones in a 70-year-old Danish population. Scand J Gastroenterol 1990;25:335-340
3. Newman HF, Northup JD. The autopsy incidence of gallstones. Intern Abstr Surg 1959;109:1-13
4. The MICOL Group. Prevalence of gallstone disease in 18 Italian population samples: first results from the MICOL study. In: Capocaccia L, Ricci G, Angelico F, Angelico M, Attili AF, Lalloni F; editors, Recent advances in the epidemiology and prevention of gallstone disease. Boston: Kluwer; 1991. p. 37-44
5. Admirand WH, Small DM. The physicochemical basis of cholesterol gallstone formation in man. J Clin Invest 1968;47:1043
6. Gilloteaux J, Karkare S, Don AQ, Sexton R. Cholelithiasis induced in the Syrian hamster: evidence of intramucinous process and down regulation of 7alpha-hydroxylase (CYP7) by medroxyprogesterone. Microsc Res Tech 1997;39:56-70
7. Schoenfield LU, Lachin JM, the Steering Committee, and the National Gallstone Study Group. Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: the National Cooperative Gallstone Study. Ann Intern Med 1981;95:257-282
8. Scragg RK, Calvert GD, Oliver JR. Plasma lipids and insulin in gallstone disease: a case control study. Br Med J 1984;289:521
9. Thijs C, Knipschild P. Serum lipids and gallstones: a case-control study. Gastroenterology 1990;99:843
10. Marks JW, Cleary PA, Albers JJ. Lack of correlation between serum lipoproteins and biliary cholesterol saturation in patients with gallstones. Dig Dis Sci 1984;29:1118
11. Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005;352(21):2184-2192
12. Kaiserman N, Vinker S, Kaiserman I. Statins do not decrease the risk for wet age-related macular degeneration. Curr Eye Res 2009;34(4):304-310
13. Kaiserman I, Kaiserman N, Elhayany A, Vinker S. Topical beta-blockers are not associated with an increased risk of treatment for depression. Ophthalmology 2006;113(7):1077-1080
14. Rubin DB. Inference and missing data. Biometrika 1976;63:581-592
15. Rubin DB. Multiple imputation for nonresponse in surveys, Wiley & Sons, New York; 1987
16. Chapman BA, Wilson IR, Frampton CM, et al. Prevalence of gallbladder disease in diabetes mellitus. Dig Dis Sci 1996;41(11):2222-2228
17. Marks JW, Cleary PA, Albers JJ. Lack of correlation between serum lipoproteins and biliary cholesterol saturation in patients with gallstones. Dig Dis Sci 1984;29(12):1118-1122
18. Larsen ML, Illingworth DR. Drug treatment of dyslipoproteinemia. Med Clin North Am 1994;78(1):225-245
19. Loria P, Bertolotti M, Cassinadri MT, et al. Short-term effects of simvastatin on bile acid synthesis and bile lipid secretion in human subjects. Hepatology 1994;19:882-888
20. Mazzella G, Parini P, Festi D, et al. Effects of simvastatin, ursodeoxycholic acid and simvastatin plus ursodeoxycholic acid on biliary lipid secretion and cholic acid kinetics in nonfamilial hypercholesterolemia. Hepatology 1992;15:1072-1078
21. Duane WC, Hunninghake DB, Freeman ML, et al. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology 1988;8:1147-1150
22. Mitchell JC, Logan GM, Stone BG, et al. Effects of lovastatin on biliary lipid secretion and bile acid metabolism in humans. J Lipid Res 1991;32:71-78
23. Logan G, Duane WC. Lovastatin added to ursodeoxycholic acid further reduces biliary cholesterol saturation. Gastroenterology 1990;98:15672-15676
24. Smit JW, van Erpecum KJ, Renooij W, et al. The effects of the 3-hydroxy, 3-methylglutaryl coenzyme A reductase inhibitor pravastatin on bile composition and nucleation of cholesterol crystals in cholesterol gallstone disease. Hepatology 1995;21:1523-1529
25. Smit JW, van Erpecum KJ, Portincasa P, et al. Effects of simvastatin and cholestyramine on bile lipid composition and gallbladder motility in patients with hypercholesterolaemia. Gut 1995;37:654-656
26. Wilson IR, Hurrell MA, Pattinson NR, et al. The effect of simvastatin and bezafibrate on bile composition and gall-bladder emptying in female non-insulin-dependent diabetics. J Gastroenterol Hepatol 1994;9:447-451
27. Reihner E, Rudling M, Stahlberg D, et al. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med 1990;323:224-228
28. Tazuma S, Kajiyama G, Yamashita G, et al. Combination therapy with simvastatin and ursodeoxycholic acid is more effective for cholesterol gallstone dissolution than ursodeoxycholic monotherapy. J Clin Gastroenterol 1998;26:287
29. Akriviadis EA, Hatzigavriel M, Kapnias D, et al. Treatment of biliary colic with diclofenac: a randomized double-blind, placebo-controlled study. Gastroenterology 1997;113:225
30. Goldman G, Kahn PJ, Alon R, Wiznitzer T. Biliary colic treatment and acute cholecystitis prevention by prostaglandin inhibitor. Dig Dis Sci 1989;34:809
31. Thornell E, Nilsson B, Jansson R, Svanvik J. Effect of short-term indomethacin treatment on the clinical course of acute obstructive cholecystitis. Eur J Surg 1991;15:127
32. Thornell E, Jansson R, Svanvik J. Indomethacin intravenously: a new way for effective relief of biliary pain: a double blind study in man. Surgery 1981;90:468
33. Romano M, Diomede L, Sironi M, et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 2000;80:1095-1100
34. Wang HR, Li JJ, Huang CX, et al. Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappaB in human endothelial cells stimulated by C-reactive protein. Clin Chim Acta 2005;353:53-60
35. Bodmer M, Brauchli YB, Krähenbühl S, et al. Statin use and risk of gallstone disease followed by cholecystectomy. JAMA 2009;302(18):2001-2007
36. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Statin use and the risk of cholecystectomy in women. Gastroenterology 2009;136(5):1593-1600